CA2376474A1 - Peptides retro inverses derives du facteur d'inhbition de la leucemie - Google Patents

Peptides retro inverses derives du facteur d'inhbition de la leucemie Download PDF

Info

Publication number
CA2376474A1
CA2376474A1 CA002376474A CA2376474A CA2376474A1 CA 2376474 A1 CA2376474 A1 CA 2376474A1 CA 002376474 A CA002376474 A CA 002376474A CA 2376474 A CA2376474 A CA 2376474A CA 2376474 A1 CA2376474 A1 CA 2376474A1
Authority
CA
Canada
Prior art keywords
peptide
amino acid
retro
sequence shown
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376474A
Other languages
English (en)
Inventor
David E. Wright
D. Elliot Parks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myelos Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376474A1 publication Critical patent/CA2376474A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne les peptides rétro inverses dérivés du facteur d'inhibition de la leucémie (LIF) possédant entre 18 et environ 40 acides aminés et comprenant la séquence représentée dans SEQ ID NO : 1. Ces peptides ont la même activité que le LIF natif ainsi qu'une activité neurotrophique. Du fait de la liaison des acides aminés D dans les peptides, ces peptides sont moins sensibles à la dégradation protéolytique <i>in vivo</i>.
CA002376474A 1999-06-16 2000-06-16 Peptides retro inverses derives du facteur d'inhbition de la leucemie Abandoned CA2376474A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13968599P 1999-06-16 1999-06-16
US60/139,685 1999-06-16
PCT/US2000/016760 WO2000077029A1 (fr) 1999-06-16 2000-06-16 Peptides retro inverses derives du facteur d'inhbition de la leucemie

Publications (1)

Publication Number Publication Date
CA2376474A1 true CA2376474A1 (fr) 2000-12-21

Family

ID=22487838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376474A Abandoned CA2376474A1 (fr) 1999-06-16 2000-06-16 Peptides retro inverses derives du facteur d'inhbition de la leucemie

Country Status (6)

Country Link
EP (1) EP1183266A4 (fr)
JP (2) JP2003502341A (fr)
AU (1) AU5622700A (fr)
CA (1) CA2376474A1 (fr)
IL (2) IL147095A0 (fr)
WO (1) WO2000077029A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
AU2001237132B2 (en) * 2000-03-03 2006-04-27 Amrad Corporation Limited A method of treatment
CA2401989A1 (fr) * 2000-03-03 2001-09-07 The Walter And Eliza Hall Institute Of Medical Research Methode de traitement
CA2645245A1 (fr) * 2006-03-31 2007-10-11 Queen's University At Kingston Compositions et procedes de traitement de l'atherosclerose
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843892A (en) * 1989-12-18 1998-12-01 California Institute Of Technology Stimulation of nerve growth and/or vitality
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
EP0979238A4 (fr) * 1997-03-05 2000-08-23 Univ California Procedes pour soulager les douleurs neuropathiques
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides

Also Published As

Publication number Publication date
WO2000077029A1 (fr) 2000-12-21
IL147095A (en) 2010-12-30
EP1183266A4 (fr) 2002-10-23
IL147095A0 (en) 2002-08-14
JP2003502341A (ja) 2003-01-21
JP2011144184A (ja) 2011-07-28
EP1183266A1 (fr) 2002-03-06
AU5622700A (en) 2001-01-02

Similar Documents

Publication Publication Date Title
CA2168029C (fr) Peptides derives de la prosaposine et de la cytokine, agents therapeutiques
AU751034B2 (en) Cyclic prosaposin-derived peptides and uses thereof
JP2011144184A (ja) 白血病阻害因子に由来するレトロ−インベルソなペプチド
US20110190213A1 (en) Retro-inverso peptides derived from interleukin-3
US6458357B1 (en) Retro-inverso neurotrophic and analgesic peptides
JP2011137019A (ja) インターロイキン−３から誘導されるレトロ−インベルソペプチド
US8063016B2 (en) Retro-inverso peptides derived from interleukin-6
US7754690B2 (en) Method of using retro inverso peptides derived from leukemia inhibitory factor
JP4786843B2 (ja) インターロイキン−６から誘導されるレトロ−インベルソペプチド
US20020128193A1 (en) Retro-inverso prosaposin-derived peptides and use thereof

Legal Events

Date Code Title Description
FZDE Discontinued